Acomplia Now Available In Ireland
"Sanofi-aventis Ireland Ltd. announced today, that ACOMPLIA(R) (rimonabant 20mg/day), is available from today, 1st November 2006.
ACOMPLIA(R) is the first in a new class of drugs that target cardiometabolic risk factors such as abdominal obesity, insulin resistance, cholesterol and elevated triglycerides(i). It is licensed for use as an adjunct to diet and exercise for the treatment of obese patients (BMI greater than or equal to 30kg/m2), or overweight patients (BMI >27kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidaemia(1).
Ireland is the third country in the world to have launched ACOMPLIA(R) and the treatment has been welcomed by physicians across the country.
"Rimonabant (Acomplia) addresses the multiple cardiometabolic risk factors that put patients at risk for cardiovascular disease and type 2 diabetes" said Dr. Seamus Sreenan, Consultant Endocrinologist, Connolly Hospital, Blanchardstown, Dublin 15. He continued "ACOMPLIA(R) is an important advancement which will offer benefits beyond current treatments for individual risk factors such as blood pressure, cholesterol and diabetes and I applaud the foresight of early access to this valuable medicine for patients in Ireland".
acomplia
rimonabant
accomplia
0 Comments:
Post a Comment
<< Home